Effect of the alpha 2 adrenoreceptor antagonist, idazoxan, on motor disabilities in MPTP-treated monkey

E Bezard; C Brefel; F Tison; H Peyro-Saint-Paul; P Ladure; O Rascol; C E Gross

doi:10.1016/s0278-5846(99)00067-6

Effect of the alpha 2 adrenoreceptor antagonist, idazoxan, on motor disabilities in MPTP-treated monkey

Prog Neuropsychopharmacol Biol Psychiatry. 1999 Oct;23(7):1237-46. doi: 10.1016/s0278-5846(99)00067-6.

Authors

E Bezard¹, C Brefel, F Tison, H Peyro-Saint-Paul, P Ladure, O Rascol, C E Gross

Affiliation

¹ Laboratoire de Neurophysiologie, CNRS UMR 5543, Université de Bordeaux II, France.

PMID: 10581645
DOI: 10.1016/s0278-5846(99)00067-6

Abstract

1. The motor effect of the alpha 2 adrenoreceptor antagonist, idazoxan, was compared to that of L-dopa in MPTP-treated monkeys. 2. Idazoxan 2.0 mg/kg improved parkinsonian motor abnormalities which was comparable to the effects of a minimal effective dose of L-dopa. 3. At 2.0 and 5.0 mg/kg, the parkinsonian rigidity was the item most frequently alleviated by idazoxan (respectively 63.6% and 68.2%). 4. These findings provide support for the therapeutic utility of alpha 2 antagonists in the treatment of Parkinson's disease.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / pharmacology*
Adrenergic alpha-Antagonists / pharmacology*
Animals
Disease Models, Animal
Dopamine Agents / pharmacology*
Dose-Response Relationship, Drug
Female
Idazoxan / pharmacology*
Macaca fascicularis
Motor Skills Disorders / chemically induced*
Motor Skills Disorders / drug therapy
Parkinson Disease / drug therapy

Substances

Adrenergic alpha-Antagonists
Dopamine Agents
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Idazoxan